Working for a biotech company means navigating highly complex market dynamics. Even in today’s connected world, each country comes with its own distinct regulatory, commercial, and pricing and market access (P&MA) requirements. The differences between the US and Europe are particularly pronounced, making nuanced understanding and careful planning essential for biotech firms aiming to succeed.
Watch the second episode of the Better Biotech Growth webinar series to explore how to maximize patient reach across regions, particularly for assets in mid-stage development and beyond.
This webinar recording covers:
- The key drivers of go-to-market (GTM) strategy selection, and why one approach may be better suited for your organization than another
- How to assess the essential elements of GTM strategy
- The nuances European biotechs face when entering the US market and vice versa
- The foundational assessments needed to inform GTM strategy decisions
